194 related articles for article (PubMed ID: 33443370)
1. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents.
The RESPOND Study Group
AIDS; 2021 May; 35(6):869-882. PubMed ID: 33443370
[TBL] [Abstract][Full Text] [Related]
2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
3. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Byonanebye DM; Polizzotto MN; Neesgaard B; Sarcletti M; Matulionyte R; Braun DL; Castagna A; de Wit S; Wit F; Fontas E; Vehreschild JJ; Vesterbacka J; Greenberg L; Hatleberg C; Garges H; Gallant J; Volny Anne A; Öllinger A; Mozer-Lisewska I; Surial B; Spagnuolo V; Necsoi C; van der Valk M; Mocroft A; Law M; Ryom L; Petoumenos K;
HIV Med; 2022 Sep; 23(8):895-910. PubMed ID: 35233903
[TBL] [Abstract][Full Text] [Related]
4. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
5. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
6. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
[TBL] [Abstract][Full Text] [Related]
7. Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.
Richter E; Bornemann L; Korencak M; Alter G; Schuster M; Esser S; Boesecke C; Rockstroh J; Gunzer M; Streeck H
J Virol; 2022 Mar; 96(5):e0173021. PubMed ID: 35019724
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
9. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
10. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
[TBL] [Abstract][Full Text] [Related]
11. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
12. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.
Neesgaard B; Mocroft A; Zangerle R; Wit F; Lampe F; Günthard HF; Necsoi C; Law M; Mussini C; Castagna A; Monforte AD; Pradier C; Chkhartisvilli N; Reyes-Uruena J; Vehreschild JJ; Wasmuth JC; Sönnerborg A; Stephan C; Greenberg L; Llibre JM; Volny-Anne A; Peters L; Pelchen-Matthews A; Vannappagari V; Gallant J; Rieger A; Youle M; Braun D; De Wit S; Petoumenos K; Borghi V; Spagnuolo V; Tsertsvadze T; Lundgren J; Ryom L;
PLoS One; 2020; 15(12):e0243625. PubMed ID: 33382756
[TBL] [Abstract][Full Text] [Related]
13. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Ranzenigo M; Gianotti N; Galli L; Poli A; Mastrangelo A; Bruzzesi E; Chiurlo M; Nozza S; Bossolasco S; Spagnuolo V; Mancusi D; Termini R; Carini E; Lazzarin A; Castagna A
Drug Des Devel Ther; 2022; 16():1975-1982. PubMed ID: 35783200
[TBL] [Abstract][Full Text] [Related]
14. Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage.
Benson C; Emond B; Lefebvre P; Lafeuille MH; Côté-Sergent A; Tandon N; Chow W; Dunn K
J Manag Care Spec Pharm; 2020 Feb; 26(2):129-141. PubMed ID: 31747358
[TBL] [Abstract][Full Text] [Related]
15. Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV.
Kamkwalala AR; Wang K; O'Halloran J; Williams DW; Dastgheyb R; Fitzgerald KC; Spence AB; Maki PM; Gustafson DR; Milam J; Sharma A; Weber KM; Adimora AA; Ofotokun I; Sheth AN; Lahiri CD; Fischl MA; Konkle-Parker D; Xu Y; Rubin LH
AIDS Behav; 2021 Jan; 25(1):225-236. PubMed ID: 32638219
[TBL] [Abstract][Full Text] [Related]
16. Weight gain after antiretroviral therapy initiation in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Zhao X; Prajapati G; Tse J; Near AM; Kumar PN
Curr Med Res Opin; 2023 Jul; 39(7):997-1006. PubMed ID: 37334707
[TBL] [Abstract][Full Text] [Related]
17. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
Trickey A; Zhang L; Gill MJ; Bonnet F; Burkholder G; Castagna A; Cavassini M; Cichon P; Crane H; Domingo P; Grabar S; Guest J; Obel N; Psichogiou M; Rava M; Reiss P; Rentsch CT; Riera M; Schuettfort G; Silverberg MJ; Smith C; Stecher M; Sterling TR; Ingle SM; Sabin CA; Sterne JAC
Lancet HIV; 2022 Jun; 9(6):e404-e413. PubMed ID: 35659335
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
Mocroft A; Neesgard B; Zangerle R; Rieger A; Castagna A; Spagnuolo V; Antinori A; Lampe FC; Youle M; Vehreschild JJ; Mussini C; Borghi V; Begovac J; Duvivier C; Gunthard HF; Rauch A; Tiraboschi J; Chkhartishvili N; Bolokadze N; Wit F; Wasmuth JC; De Wit S; Necsoi C; Pradier C; Svedhem V; Stephan C; Petoumenos K; Garges H; Rogatto F; Peters L; Ryom L;
HIV Med; 2020 Oct; 21(9):599-606. PubMed ID: 32588958
[TBL] [Abstract][Full Text] [Related]
19. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines.
El Bouzidi K; Jose S; Phillips AN; Pozniak A; Ustianowski A; Gompels M; Winston A; Schaap A; Dunn DT; Sabin CA;
AIDS; 2020 Oct; 34(12):1823-1831. PubMed ID: 32516283
[TBL] [Abstract][Full Text] [Related]
20. Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.
Padmapriyadarsini C; Ramesh Kumar S; Terrin N; Narendran G; Menon PA; Ramachandran G; Subramanyan S; Venkatesan P; Wanke C; Swaminathan S
Clin Infect Dis; 2011 Feb; 52(4):540-6. PubMed ID: 21252141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]